281-296-7300

  • Awards
  • Careers
logo
  • About
    • About VGXI
    • Leadership
    • VGXI Mission
    • Awards
    • Careers
  • Services
    • Manufacturing Services
    • cGMP Plasmid
    • HD Plasmid
    • Pre-Clinical Plasmid
    • Additional Services
  • VGXI Process
    • VGXI Manufacturing Process
    • Analytical Testing
    • Quality Systems
  • Resource Center
    • News
    • Events
    • FAQs
    • Whitepapers
    • Posters & Presentations
  • Contact Us
  • Awards
  • Careers

Recent News

VGXI Official COVID-19 Statement

March 31, 2022

To our Valued Clients and Business Partners, VGXI’s top priority is to continue delivering the highest quality DNA products and services while ensuring the security and safety of our team. VGXI is actively monitoring the evolving situation and will continue to provide updates as new information becomes available. Manufacturing activities have been… Read More »

VGXI Completes Land Purchase and Advances Design Development for New Manufacturing Facility

August 6, 2020

Plasmid DNA Manufacturer VGXI, Inc. Completes Land Purchase and Proceeds with Design Development Phase for New Expanded Manufacturing Facility. The Woodlands, TX – VGXI, a highly regarded CDMO supporting the gene therapy and DNA vaccine industries, announces it has closed on the purchase of greenfield for a new, expanded manufacturing facility. The… Read More »

VGXI’s Statement on the Recent Litigation Involving Inovio Pharmaceuticals, Inc. (“Inovio”) in Pennsylvania State Court

June 4, 2020

Update June 26, 2020: VGXI and GeneOne are pleased with the court’s decision in our favor protecting our company’s intellectual property rights. We have always been willing to manufacture any vaccine candidate for Covid-19, and want to help find a cure. Original Post on June 04, 2020: VGXI was surprised by Inovio’s… Read More »

VGXI Enables Rapid GMP DNA Manufacturing Timeline for Geneos Therapeutics Personalized Cancer Immunotherapy

May 19, 2020

VGXI, Inc., Geneos Therapeutics’ CDMO partner, completes manufacturing of first GMP Lot under Clinical Manufacturing Supply Agreement. THE WOODLANDS,TX AND PLYMOUTH MEETING, PA – Leading plasmid DNA contract manufacturer VGXI, Inc. announced it has completed accelerated cGMP manufacturing of the first clinical batch of a personalized neoantigen vaccine for its client Geneos… Read More »

Deison Technology Park Provides Increased Capacity for VGXI to Manufacture Vaccines

April 24, 2020

News article released this week by the Conroe Economic Development Council announced VGXI’s planned 240,000 square-foot facility to meet increasing demand for high quality plasmid DNA products and services http://www.conroeedc.org/deison-technology-park-provides-increased-capacity-for-vgxi/

VGXI Supports Rapid Timeline to Clinical Testing for Coronavirus Vaccine

April 6, 2020

Plasmid CDMO VGXI, Inc. Completes Manufacturing and Release of a Vaccine against COVID-19 in Record-Setting Time The Woodlands, TX – VGXI, an industry leading provider of GMP grade plasmid DNA for vaccines and gene therapies, announced it has completed manufacturing and release of a DNA vaccine to combat the COVID-19 pandemic. VGXI… Read More »

VGXI Recognized as Best CMO Finalist for the 2020

March 4, 2020

Texas-based plasmid DNA manufacturer VGXI, Inc. recognized as a finalist for Best CMO for the ViE Awards of the World Vaccine Congress The Woodlands, TX – VGXI, Inc., a uniquely specialized CDMO providing high quality plasmid DNA-based products and services, announced it has been nominated as a finalist in the category of… Read More »

VGXI to Exhibit at Gene Therapy for Rare Disorders

February 27, 2020

The 4th Annual Gene Therapy for Rare Disorders will focus on overcoming the late-stage commercial challenges drug developers face when delivering gene therapies to market. Visit VGXI at Booth #6 or meet with one of our representatives during the conference to learn more about how our plasmid manufacturing services can support your gene… Read More »

VGXI to Exhibit at the 2020 World Vaccine Congress

February 27, 2020

The World Vaccine Congress is a critical strategic partnering event for the global vaccine industry. Visit our Booth #310 or meet with a representative from VGXI during the conference in April to learn more about how our plasmid manufacturing services can support your vaccine program! Each year at WVC the winners are announced… Read More »

VGXI to Manufacture Vaccine Against Novel Coronavirus Under CEPI Funded Collaboration

January 29, 2020

Texas-based plasmid DNA Manufacturer VGXI, Inc. to Enable Accelerated Production of a Vaccine against the 2019 Novel Coronavirus in a CEPI Funded Collaboration The Woodlands, TX – VGXI, a world leading contract manufacturer of clinical grade DNA plasmid, announced it will start production of a DNA vaccine against the novel coronavirus (2019-nCoV)… Read More »

VGXI, Inc. Establishes Pilot mRNA Manufacturing Capabilities

December 6, 2019

Under a Technology License Agreement with the Houston Methodist Research Institute, Contract Developer and Manufacturer VGXI Achieves Key Milestones with Establishment of Pilot Production Capabilities for RNA-Based Medicines. The Woodlands, TX – VGXI announces successful implementation of new RNA production services through completion of all Phase II initiatives as part of a… Read More »

VGXI Selects BE&K as Design-Build Partner for New Manufacturing Facility

December 3, 2019

Plasmid DNA Manufacturer VGXI, Inc. Selects BE&K Building Group as its Design-Build Partner for the Initial Phase of its New and Expanded Manufacturing Facility December 3, 2019, The Woodlands, TX – VGXI, a highly regarded CDMO supporting the gene therapy and DNA vaccine industries, announces it has chosen the integrated construction services… Read More »

VGXI to Exhibit at the Annual ISV Congress

October 7, 2019

The ISV Annual Congress is the world’s largest scientific conference in the field of vaccines and covers a broad range of topics related to vaccines and immunotherapies. We welcome you to stop by VGXI’s booth or schedule a meeting with one of our representatives during the conference to learn more about VGXI’s plasmid manufacturing… Read More »

  • « Previous
  • 1
  • 2
  • 3
  • 4
  • …
  • 18
  • Next »

Archives

  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • About
  • Services
  • VGXI Process
  • Contact Us
  • Careers
  • Awards
  • Resource Center
logo white

281-296-7300
2700 Research Forest Drive, Suite 180
The Woodlands, Texas 77381, USA

Teko Font
Please enter your name.
Please enter a valid email address.
Sign Up

Thanks for subscribing! Please check your email for further instructions.

Something went wrong. Please check your entries and try again.

© 2021 VGXI, Inc. All Rights Reserved.Terms | Privacy Policy